<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d140">
    <sentence id="DDI-MedLine.d140.s0" text="Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d140.s0.e0" charOffset="27-36"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s0.e1" charOffset="182-193"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d140.s0.p0" e1="DDI-MedLine.d140.s0.e0"
            e2="DDI-MedLine.d140.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s1" text="OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ">
        <entity id="DDI-MedLine.d140.s1.e0" charOffset="82-91"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s1.e1" charOffset="97-108"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d140.s1.e2" charOffset="116-126"
            type="drug" text="ciclosporin"/>
        <pair id="DDI-MedLine.d140.s1.p0" e1="DDI-MedLine.d140.s1.e0"
            e2="DDI-MedLine.d140.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d140.s1.p1" e1="DDI-MedLine.d140.s1.e0"
            e2="DDI-MedLine.d140.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d140.s1.p2" e1="DDI-MedLine.d140.s1.e1"
            e2="DDI-MedLine.d140.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s2" text="METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. ">
        <entity id="DDI-MedLine.d140.s2.e0" charOffset="127-136"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s2.e1" charOffset="197-208"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d140.s2.e2" charOffset="214-223"
            type="drug" text="prednisone"/>
        <pair id="DDI-MedLine.d140.s2.p0" e1="DDI-MedLine.d140.s2.e0"
            e2="DDI-MedLine.d140.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d140.s2.p1" e1="DDI-MedLine.d140.s2.e0"
            e2="DDI-MedLine.d140.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d140.s2.p2" e1="DDI-MedLine.d140.s2.e1"
            e2="DDI-MedLine.d140.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s3" text="Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. ">
        <entity id="DDI-MedLine.d140.s3.e0" charOffset="43-52"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s3.e1" charOffset="58-69"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d140.s3.p0" e1="DDI-MedLine.d140.s3.e0"
            e2="DDI-MedLine.d140.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s4" text="Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. ">
        <entity id="DDI-MedLine.d140.s4.e0" charOffset="0-9" type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s5" text="Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. ">
        <entity id="DDI-MedLine.d140.s5.e0" charOffset="0-9" type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s6" text="Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. ">
        <entity id="DDI-MedLine.d140.s6.e0" charOffset="25-36"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d140.s6.e1" charOffset="89-98"
            type="drug" text="everolimus"/>
        <pair id="DDI-MedLine.d140.s6.p0" e1="DDI-MedLine.d140.s6.e0"
            e2="DDI-MedLine.d140.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s7" text="RESULTS: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. ">
        <entity id="DDI-MedLine.d140.s7.e0" charOffset="9-18"
            type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s8" text="Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. "/>
    <sentence id="DDI-MedLine.d140.s9" text="There was evidence for longitudinal stability in AUC of everolimus during the course of the study. ">
        <entity id="DDI-MedLine.d140.s9.e0" charOffset="56-65"
            type="drug" text="everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s10" text="The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%. "/>
    <sentence id="DDI-MedLine.d140.s11" text="Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. "/>
    <sentence id="DDI-MedLine.d140.s12" text="There was an increasing incidence of transient thrombocytopenia (or =100 x 10(9)/L) with increasing everolimus AUC (P = .03). ">
        <entity id="DDI-MedLine.d140.s12.e0" charOffset="100-109"
            type="drug" text="everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s13" text="Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). ">
        <entity id="DDI-MedLine.d140.s13.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-MedLine.d140.s13.e1" charOffset="152-161"
            type="drug" text="everolimus"/>
        <pair id="DDI-MedLine.d140.s13.p0" e1="DDI-MedLine.d140.s13.e0"
            e2="DDI-MedLine.d140.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s14" text="CONCLUSIONS: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. ">
        <entity id="DDI-MedLine.d140.s14.e0" charOffset="13-22"
            type="drug" text="Everolimus"/>
    </sentence>
    <sentence id="DDI-MedLine.d140.s15" text="For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.">
        <entity id="DDI-MedLine.d140.s15.e0" charOffset="22-31"
            type="drug" text="everolimus"/>
        <entity id="DDI-MedLine.d140.s15.e1" charOffset="77-88"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d140.s15.p0" e1="DDI-MedLine.d140.s15.e0"
            e2="DDI-MedLine.d140.s15.e1" ddi="false"/>
    </sentence>
</document>
